尊龙凯时 - 人生就是搏!
Skip to content
Home
Management Team
Pipeline
Collaboration
News
Contact Us
中文
Toggle Menu
Officially Approved. Anfangning (KRAS G12C Inhibitor Garsorasib) Receives Market Authorization from the National Medical Products Administration (NMPA) of China
11/11/2024
2024 WCLC | Latest Progress of Garsorasib (D-1553) in Treating KRAS G12C-Mutant Lung Cancer: Phase 2 Study Updates
09/10/2024
Garsorasib (D-1553) New Indication Added to Breakthrough Therapy Designation Program
06/13/2024
Garsorasib (D-1553) Phase II Study Results for Lung Cancer Published in Prestigious International Journal
06/11/2024
InventisBio to Present Phase II Clinical Data of Garsorasib (D-1553) for Lung Cancer at the 2024 AACR Annual Meeting
03/13/2024
© InventisBio Co., Ltd 沪ICP备2021024579号-1 沪公网安备31011502020033
Home
Management Team
Pipeline
Collaboration
News
Contact Us
中文
友情链接:
j9九游会官网入口首页
k1体育
拉斯维加斯9888
ng28南宫
PG电子
